Clinical Trial Update: Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients [Phase 2]

View source ↗

Summary

Phase 2 trial comparing trastuzumab to lapatinib as neoadjuvant therapy in HER2-positive breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Lapatinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-11-02